Intellia Therapeutics, Inc. (NASDAQ:NTLA) Holdings Increased by Chevy Chase Trust Holdings LLC

Chevy Chase Trust Holdings LLC lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLAFree Report) by 8.4% during the 1st quarter, HoldingsChannel.com reports. The firm owned 1,074,610 shares of the company’s stock after acquiring an additional 83,435 shares during the quarter. Chevy Chase Trust Holdings LLC’s holdings in Intellia Therapeutics were worth $29,563,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Blue Trust Inc. acquired a new position in shares of Intellia Therapeutics in the 4th quarter worth approximately $26,000. Signaturefd LLC increased its position in shares of Intellia Therapeutics by 89.3% in the fourth quarter. Signaturefd LLC now owns 1,592 shares of the company’s stock worth $49,000 after acquiring an additional 751 shares in the last quarter. Daiwa Securities Group Inc. increased its position in shares of Intellia Therapeutics by 35.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 3,056 shares of the company’s stock worth $93,000 after acquiring an additional 793 shares in the last quarter. Spire Wealth Management increased its position in shares of Intellia Therapeutics by 3,789.0% in the fourth quarter. Spire Wealth Management now owns 3,889 shares of the company’s stock worth $119,000 after acquiring an additional 3,789 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in shares of Intellia Therapeutics in the fourth quarter worth approximately $206,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on NTLA. Truist Financial reissued a “buy” rating and issued a $120.00 target price on shares of Intellia Therapeutics in a research report on Monday, June 24th. BMO Capital Markets boosted their price objective on shares of Intellia Therapeutics from $62.00 to $70.00 and gave the company an “outperform” rating in a research report on Friday, May 10th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $73.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, June 27th. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research note on Thursday, June 27th. Finally, Wedbush reiterated a “neutral” rating and issued a $29.00 target price on shares of Intellia Therapeutics in a research note on Tuesday, April 23rd. One analyst has rated the stock with a sell rating, four have issued a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, Intellia Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $69.00.

Get Our Latest Report on Intellia Therapeutics

Intellia Therapeutics Trading Up 2.7 %

NASDAQ NTLA traded up $0.59 on Wednesday, hitting $22.85. 601,261 shares of the company were exchanged, compared to its average volume of 1,559,284. The firm has a 50 day moving average of $23.95 and a two-hundred day moving average of $25.87. The company has a market cap of $2.20 billion, a P/E ratio of -4.15 and a beta of 1.82. Intellia Therapeutics, Inc. has a 1-year low of $19.37 and a 1-year high of $46.50.

Intellia Therapeutics (NASDAQ:NTLAGet Free Report) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($1.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.35) by $0.29. The company had revenue of $28.94 million for the quarter, compared to analyst estimates of $15.60 million. Research analysts anticipate that Intellia Therapeutics, Inc. will post -4.98 EPS for the current fiscal year.

Intellia Therapeutics Company Profile

(Free Report)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

Featured Articles

Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLAFree Report).

Institutional Ownership by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.